Clinical Trial Update: Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy [Phase 2]

View source ↗

Summary

Phase 2 study of TAC-101 as second-line treatment in advanced hepatocellular carcinoma after sorafenib was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• TAC-101

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2022-02-01